Sign in

CIK 0001650648 · Non-accelerated filer<br>Smaller reporting company

4D Molecular Therapeutics, Inc.

Sign in to watch
Ticker
FDMT
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
473506994
Phone
5105052680
Business address
5858 HORTON STREET #455, EMERYVILLE, CA, 94608
Former names
4D Molecular Therapeutics Inc., 4D Molecular Therapeutics Inc
  1. 4 Planned sale Chief Executive Officer sold 12,930 shares at $23.10 ($298,711)
  2. 4 Planned sale Chief Legal Officer sold 1,750 shares at $23.71 ($41,494)
  3. 4 Derivatives Options or other derivatives
  4. 4 Derivatives Options or other derivatives
  5. 4 Derivatives Options or other derivatives
  6. 4 Derivatives Options or other derivatives
  7. 4 Derivatives Options or other derivatives
  8. 4 Derivatives Options or other derivatives
  9. 4 Planned sale Chief Legal Officer sold 1,750 shares at an average $25.45 ($44,541)
  10. 4 Planned sale Chief Legal Officer sold 1,750 shares at $25.74 ($45,045)
  11. 4 Planned sale Chief Legal Officer sold 8,153 shares at $31.78 ($259,102)
  12. 4 Planned sale Chief Legal Officer sold 5,833 shares at $35.04 ($204,410)
  13. 4 Planned sale Chief Legal Officer sold 1,750 shares at $31.27 ($54,723)
  14. 4 Planned sale Chief Legal Officer sold 1,909 shares at $30.00 ($57,270)
  15. 4 Planned sale Chief Legal Officer sold 1,750 shares at $27.67 ($48,423)
  16. 4 Planned sale Chief Legal Officer sold 6,244 shares at $27.50 ($171,710)
  17. 4 Planned sale Chief Executive Officer sold 92,001 shares at $27.13 ($2,495,822)
  18. 4 Planned sale Chief Medical Officer sold 24,552 shares at $30.05 ($737,788)
  19. 3/A Insider 3/A
  20. 4 Open-market sale Chief Executive Officer sold 5,696 shares at $18.41 ($104,851)

Page 4 of 9 · 170 filings